Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Bibliographic Details
Main Authors:	Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Format:	Online
Language:	English
Published:	BioMed Central 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991225/

Similar Items

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
by: Postow, Michael A, et al.
Published: (2014)

Hiding the road signs that lead to tumor immunity
by: Schaer, David A., et al.
Published: (2011)

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
by: Gardiner, David, et al.
Published: (2013)

Dapagliflozin: BMS 512148; BMS-512148
Published: (2012)

Myeloid-derived suppressor cells and the efficacy of CD8+ T-cell immunotherapy
by: Lesokhin, Alexander M., et al.
Published: (2013)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
by: Tsai, Katy K., et al.
Published: (2015)

BRITOIL & BMS
Published: (1988)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
by: Schaer, David A, et al.
Published: (2014)

The conformal BMS group
by: Sasha J. Haco, et al.
Published: (2017-11-01)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
by: Postow, Michael, et al.
Published: (2014)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
by: Irena Tan, et al.
Published: (2018-07-01)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
by: Suozzi, Kathleen C., et al.
Published: (2016)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
by: Holmgaard, Rikke B., et al.
Published: (2016)

BMS supertranslations and not so soft gravitons
by: Eduardo Conde, et al.
Published: (2017-05-01)

B2BMS v FM
Published: (2001)

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
by: Selby, Mark J., et al.
Published: (2016)

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
by: Selby, Mark J., et al.
Published: (2016)

Focus on Nivolumab in NSCLC
by: Cortinovis, Diego L., et al.
Published: (2016)

Into the Clinic With Nivolumab and Pembrolizumab
by: Shu, Catherine A., et al.
Published: (2016)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
by: Yuan, Jianda, et al.
Published: (2013)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
by: Page, David B, et al.
Published: (2014)

The delicate balance of melanoma immunotherapy
by: Gyorki, David E, et al.
Published: (2013)

Generalizing the $$\mathfrak {bms}_{3}$$ bms3 and 2D-conformal algebras by expanding the Virasoro algebra
by: Ricardo Caroca, et al.
Published: (2018-03-01)

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
by: Weber, Jeffrey, et al.
Published: (2015)

Coordination chemistry of organotin (IV) complexes with ono-donor ligands
by: Mayuran, Perumal
Published: (2009)

Well-posedness and computation of solutions of a regularized Benjamin-Ono system
by: Felipe Alexander Pipicano, et al.
Published: (2016-01-01)

Synthesis and Applications of (ONO Pincer)Ruthenium‐Complex‐Bound Norvalines
by: Isozaki, Katsuhiro, et al.
Published: (2016)

Ipilimumab in patients with melanoma and autoimmune disease
by: Kyi, Chrisann, et al.
Published: (2014)

A Case of Nivolumab-Induced Myositis
by: Fox, Eric, et al.
Published: (2016)

BMS1 Is Mutated in Aplasia Cutis Congenita
by: Marneros, Alexander G.
Published: (2013)

Centrally extended BMS4 Lie algebroid
by: Glenn Barnich
Published: (2017-06-01)

BMS group at spatial infinity: the Hamiltonian (ADM) approach
by: Marc Henneaux, et al.
Published: (2018-03-01)

Asymptotic dynamics in perturbative quantum gravity and BMS supertranslations
by: Sangmin Choi, et al.
Published: (2018-01-01)

BMS and PC heads EC research programme
Published: (2000)

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
by: Hirschhorn-Cymerman, Daniel, et al.
Published: (2012)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
by: Budhu, Sadna, et al.
Published: (2013)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
by: Budhu, Sadna, et al.
Published: (2014)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
by: Zappasodi, Roberta, et al.
Published: (2014)